Install
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
- 725articles · 365d
- 1+ day agolatest article
- Sep 14, 2025earliest in window
- 96%with images
- 288avg words
- Medical 457
- Business & Industrial 430
- Economy, Business & Finance 358
- Health & Wellness 262
- Health 208
- Finance & Business 198
- Science & Technology 126
- Science & Nature 37
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
HHS Confirms Four Senior FDA Leaders, Including Agency's First-Ever AI Deputy Commissioner
4+ day, 21+ hour ago (449+ words) Pharmaceutical Executive...
Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq
1+ week, 4+ day ago (279+ words) Alteogen grants Novartis options to develop subcutaneous formulations using its ALT-B4 hyaluronidase platform, NewBiologix and Synastra partner to develop a stable producer cell line, and RedHill acquires global commercialization rights to Ferring's Rebyota and Clenpiq. Alteogen Inc. entered into an…...
Pharmaceutical Executive Daily: Nine Companies Strike Deals for MFN Pricing
1+ week, 5+ day ago (82+ words) Nine Companies Strike Deals for MFN Pricing | PharmExec Pharmaceutical Executive The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA flu vaccine into Phase III, and Simcere Zaiming licenses its tri-specific antibody…...
Trump Administration Adds Nine Drugmakers to Most-Favored-Nation Program: Report
1+ week, 6+ day ago (189+ words) The Trump administration adds nine midsize pharmaceutical companies, including Teva, UCB, Astellas, and BeOne Medicines to its Most-Favored-Nation drug pricing program. President Donald J. Trump announced nine new agreements with pharmaceutical manufacturers to lower prescription drug prices for Americans. Commonly known…...
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2+ week, 4+ day ago (485+ words) Pharmaceutical Executive President Donald Trumpâs administration is preparing to announce a new round of drug-pricing agreements with midsize biotech companies as soon as August 31,2026, according to sources familiar with the matter.1 The companies are expected to agree to provide…...
Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License???s Sentivera Lead Immunology Asset
2+ week, 4+ day ago (251+ words) Biohaven grants SK Biopharmaceuticals an exclusive worldwide license to its Kv7 ion channel platform, while Haisco licenses a preclinical type 2 inflammatory disease asset to newly formed Sentivera. Two licensing agreements this week show biotech companies turning to partnerships and Newco structures…...
What Executives and Investors Are Looking for in Pharma Companies
2+ week, 4+ day ago (258+ words) K2 Therapeutics CEO Ying Huang discusses the three priorities that define a successful biotech: unmet need, development cost, and accessible pricing. Earlier this year, Pharmaceutical Executive reported on China’s growing prominence in the pharma and biotech spaces. During this year, billions…...
Pharmaceutical Executive Daily: Hanmi Licenses HM17321 to Genentech
2+ week, 6+ day ago (84+ words) Hanmi Licenses HM17321 to Genentech | PharmExec Pharmaceutical Executive Hanmi Pharm licenses its obesity drug candidate HM17321 to Genentech, James LaValle weighs in after FDA advisors back most nominated peptides for the compounding bulks list, and Ivo Carre examines how tau- and microglia-targeted…...
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
2+ week, 6+ day ago (244+ words) Hanmi Pharm has licensed HM17321 to Genentech for up to $2.3 billion, including a $190 million upfront payment. Hanmi Pharm entered into an exclusive licensing agreement with Genentech, a member of the Roche Group, for the worldwide development, manufacturing, and commercialization of HM17321. The…...
Pharmaceutical Executive Daily: President Trump to Nominate Heidi Overton as FDA Commissioner
3+ week, 4+ day ago (383+ words) President Trump to Nominate Heidi Overton as FDA Commissioner | PharmExec Pharmaceutical Executive Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry In today's Pharmaceutical Executive Daily, President Trump moves to…...